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INTRODUCTION
Nowadays there are three main sources of in-
formation for the adverse drug reactions (ADR) re-
porting systems (9). The first one which is considered 
to be the most reliable is the health professionals (20). 
In Bulgaria, their obligation to report is regulated by 
law (8). In some countries, the only medical profes-
sionals who may report are physicians while in oth-
ers pharmacists and nurses are also included in the 
pharmacovigilance system. Since many dietary sup-
plements and Over-the-counter (OTC) medicines 
are of herbal origin, pharmacists are a very impor-
tant source of information because they are the most 
accessible health professional from the perspective of 
the patient (15).
The second source of information is data ob-
tained from the literature: medical journals, publi-
cations describing clinical cases, meta-analyses.  It is 
the obligation of the Marketing authorization holder 
to routinely review the published literature for clini-
cal cases associated with their products (8).
The third main source of information is pa-
tients. Although subjectively, they can describe and 
report reactions experienced due to their drug thera-
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py (17). Patients may report the occurrence of ADRs 
directly to the pharmacovigilance centers or to med-
ical specialists and the reports can be done orally, 
electronically or in hard copy by mail. In EU, direct 
patient reporting of ADRs has been introduced with 
Directive 2010/84 since July 2012. There are some 
member states that have had introduced patient re-
porting earlier (17).
METHODS
A computerized literature search of relevant ar-
ticles written in English regarding patients reporting 
of adverse drug events published from 1996 to 2012 
was completed in January 2013. An updated search 
of the literature was performed from September to 
October 2013.
References of interest were identified through 
searches of Medline, Scopus and Google Scholar. 
Combinations of search terms were “adverse drug re-
actions”, “patients reporting” and “adverse reactions 
reporting system”. The search terms were used alone 
or in combination. Review articles were scanned to 
find also additional eligible studies. The reference 
lists of all original articles and systematic reviews 
were hand-searched for other relevant articles. Du-
plicates were removed. Studies discussing the follow-
ing issues were included: patients’ role in the adverse 
reactions reporting systems, comparison between 
patients’ and health professionals’ reports, patients’ 
contribution to the adverse drug reactions reporting 
systems. Eventually 34 articles were selected for this 
review.
Patients’ role in the spontaneous reporting 
systems
Blekinsopp et al. (2007) published a systematic 
review of practices related to direct patients’ report-
ing of suspected ADRs (5). The review included sev-
en studies, although none of them directly examined 
patients’ spontaneous reporting. The results show, 
however, that where comparison is possible, the mes-
sages from patients and medical professionals are of 
similar quality.
Reporting of ADRs by patients has the potential 
to raise awareness about the potential harm of taking 
drugs. Under reporting of ADRs by patients we un-
derstand the adapted definition of van Grootheest “... 
drug users (parents and carers) who report suspect-
ed ADRs to the spontaneous reporting system” (31). 
Reporting of ADRs by patients has been first intro-
duced in several countries, including the USA, Can-
ada, Australia, New Zealand, Denmark, Sweden and 
the Netherlands. Later, patient reporting of ADRs 
has also been introduced in the United Kingdom 
(5,25,21,18,1).
Comparative study of suspected ADR reports 
by patients and health professionals
In 2011, a research team from the UK pub-
lished a comparative study of ADR reports from pa-
tients and health professionals (2). The purpose of 
this study was to assess the potential of patients as a 
source of spontaneous reports, to assess the charac-
teristics of patients’ messages and their real contri-
bution to the generation of signals. The results show 
that patients reported ADRs for different groups of 
drugs than health professionals thus generating new 
signals and describing suspected adverse reactions in 
sufficient detail to provide useful information on a 
possible causal relationship and impact of ADRs on 
the everyday life of the patient.
According to the authors of the study, timely 
and quality reporting of adverse drug reactions by 
patients can be fostered in several steps:
 ❖ Increasing public awareness; 
 ❖ Availability of guidelines for patient reporting; 
 ❖ Providing  information to patients on medici-
nal products under supervision by regulators; 
 ❖ Change in the way of reporting; 
 ❖ Feedback on the effects of patient reports.
Direct spontaneous reporting of ADRs by pa-
tients supports the collection of new data on drug 
safety. In countries where it is already possible it is 
observed that patient reports are more detailed and 
more accurate than those of health professionals. 
Unlike reports of physicians and pharmacists, pa-
tients often describe how ADRs affect their lives. 
Spontaneous patient reporting has some other ad-
vantaged also:
 ❖ More active involvement of patients in their 
treatment; 
 ❖ Increased adherence to drug therapy; 
 ❖ Better communication with health 
professionals; 
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 ❖ Assessment of impact of the severity of ADRs 
on the everyday life of the patient, which is gen-
erally omitted in physician’s reports.
For these reasons, reporting by patients needs 
to be implemented in national pharmacovigilance 
systems. The data obtained will allow the assessment 
of the severity and outcome of ADRs, which accord-
ing to Benichou and Solal-Celigny are leading indi-
cators of the clinical features of the cases (4).
Potential contributions of patient reports
The contribution of patient reports can be con-
sidered in two aspects – qualitative and quantitative 
(23).
Qualitative aspects
Consideration of direct patient reports is ex-
pected to improve qualitatively the periodic and fi-
nal safety reports of medicines. Avoiding the filtering 
of initial reports by physicians and pharmacists will 
lead to the inclusion in the systems of ADRs reports 
previously considered minor. Further wise, health 
professionals are not and cannot be familiar in de-
tail with all medicines on the market including their 
ADRs.
Quantitative aspects
Patient reports will increase the overall number 
of spontaneous reports which will improve the effec-
tiveness of the system. The indicator “reporting rate” 
will also increase leading to improvement in the pa-
rameters of the spontaneous reporting systems and 
raising awareness on this issue.
It should be noted that there are significant bar-
riers and constraints to the implementation in prac-
tice of direct patient reporting.
There are significant difficulties in incorporat-
ing patient reports into the existing ADR databases 
and/or construction of any new integrated system for 
post-marketing control and monitoring on various 
objective and subjective legal reasons. Such a system 
would require significant financial and personnel re-
sources of the competent authorities and organiza-
tions dealing with issues of national level.
Critical issues in direct patient reporting
Spontaneous reporting of ADRs by health pro-
fessionals is a useful method in pharmacovigilance 
and post-marketing surveillance of medicines (13). It 
has helped identify a number of issues in drug safety 
(24). There is a consensus among the scientific com-
munity that direct reporting of ADRs by patients will 
contribute to the development of pharmacovigilance 
(28,32,33). However, there are not enough studies on 
the full value of spontaneous reports from patients. 
Available comparisons show significant differences 
in serious adverse reactions, the identification of new 
ADRs and types of medicinal products and systems 
included in the reports. The interpretation of the dif-
ferences and their practical application in signal gen-
eration remains to be seen. Only Avery et al. (2011) 
investigated the effect of patient reports on the gen-
eration of signals relative to those of health profes-
sionals (2). Perhaps future comparative studies will 
try to assess the impact of patients’ spontaneous re-
ports on the functioning of the spontaneous report-
ing systems. Critical evaluation and comparison of 
data and studies on spontaneous reporting of ADRs 
directly from patients should be encouraged. These 
reports should be sent to the Pharmacovigilance cen-
ters, special centers for patients/consumers or direct-
ly to the competent authorities (19). 
Patients and their perceptions of ADRs
Efforts of health systems in recent years are spe-
cifically aimed at reducing the incidence of ADRs 
and improvement of dealing with them in ambula-
tory practice. There are numerous studies that ex-
amine the relationship between patients, their dis-
ease, their therapy and the incidence of ADRs. High-
er age, number of comorbidities and number of ac-
cepted medicines are proven risk factors for ADRs 
(10,16,30). However, these studies examine risk fac-
tors for ADRs documented or confirmed by the pa-
tients’ medical records or computer databases. The 
added value of direct patient-reported ADRs is that 
the reflected patients’ experience with ADRs is more 
important to their health status than clinical assess-
ment of ADRs (3). De Smedt,  Shiyanbola and Far-
ris argued that demographic and clinical variables 
such as age and comorbidities are not able to predict 
the risk of patient-reported ADRs (29,7). There are 
other factors such as perceptions of the disease and 
treatment, which may affect reporting of ADRs by 
patients (29). In 2011 De Smedt and coauthors pub-
lished a study which evaluated the impact of percep-
tions of the disease and the treatment of patients suf-
fering from heart failure, on the side effects report-
ed by them (7). The results show that patients with 
ADRs have negative perceptions of their disease and 
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therapy than patients without ADRs. They perceive 
their disease as more volatile, with more impact on 
the daily lives and suffer more from emotional stress. 
Also they have more reserves to therapy and believe 
that they are taking too many drugs. The authors ex-
plain the results with the example that patients suf-
fering from severe heart failure are more likely to ex-
perience more symptoms associated with the disease. 
According to Gandhi et al. (2003), this leads to in-
tensive therapy and respectively to more drug-relat-
ed problems (11,12). Another possible factor between 
the disease and possible ADRs is the lack of knowl-
edge and inability of patients to distinguish between 
the symptoms of the disease and those that are drug-
related (7). In addition, elderly patients often experi-
ence symptoms regarded as inevitable aspects of the 
aging process, rather than as a part of the disease or 
associated with drug therapy (22).
Patients with higher levels of negative beliefs 
about their illness and treatment are more vigilant 
for side effects and biased to the medicinal prod-
ucts they take (34). Concerns about their therapy can 
lead to the attribution of symptoms to the medicinal 
product and to be a sign of the level of tolerance for 
ADRs (26). Brown et al. (2006) discuss the perspec-
tive of patients for the occurrence of ADRs in ambu-
latory practice (6). After the interviews, the authors 
summarized the eight key elements that lead to the 
incidence of ADRs:
 ❖ Poor communication between doctor and 
patient; 
 ❖ Patients do not follow the instructions given to 
them by doctors; 
 ❖ Self-medication with herbs, OTC products and 
medicines without a prescription; 
 ❖ Patients do not read the leaflets of medicinal 
products; 
 ❖ Drug interactions; 
 ❖ Individual patient’s characteristics affect the 
patterns of prescribing and treatment outcomes; 
 ❖ Poor communication between patient and 
pharmacist; 
 ❖ Patients receiving inadequate medication.
Some of these elements could be affected by the 
fruitful contact between patients and pharmacists – 
adherence, possible drug interactions and more com-
prehensible medicines information (14,27).
CONCLUSION
Pharmacovigilance and spontaneous reporting 
systems have evolved significantly since their formal 
beginning in the 1970s. Today, the scope is broad-
ened and includes not only drugs, but also medi-
cal devices, cosmetics, vaccines, products of herb-
al origin, even health and medicines information. 
The sources of information are also evolving – from 
the pages of scientific journals through the develop-
ment of adverse drug reactions spontaneous report-
ing systems and conducting non-interventional post-
marketing studies to computer databases. Inclu-
sion of patients as a source of information will help 
change the perspective of pharmacovigilance. Pub-
lished studies indicate that the information received 
by them is qualitatively and quantitatively different 
from that of medical professionals. The factors that 
affect the decision of the patient’s report of an ad-
verse drug reaction and possible external influences 
that would shape their opinion and could affect the 
quality of reports are not well studied.
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